SEC Comment Letter for PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Nov 6, 2017
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: Nov. 6, 2017 · CIK: 0001157075 · Accession: 0000000000-17-039129
AI Filing Summary & Sentiment
Reasoning
Letter
September 19, 2017 Kenneth L. Waggoner Chief Executive Officer PharmaCyte Biotech, Inc. 23046 Avenida de la Carlota Suite 600 Laguna Hills, CA 92653 PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed September 13, 2017 File No. 333-220441Re: Dear Mr. Waggoner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Merrill Kraines, Esq.
Show Raw Text
September 19, 2017 Kenneth L. Waggoner Chief Executive Officer PharmaCyte Biotech, Inc. 23046 Avenida de la Carlota Suite 600 Laguna Hills, CA 92653 PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed September 13, 2017 File No. 333-220441Re: Dear Mr. Waggoner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Merrill Kraines, Esq.